This drug is the world’s first-ever CRISPR/Cas13 RNA-editing therapy for clinical use in treating neovascular age-related macular degeneration (nAMD). The US FDA has cleared an investigational new ...

Vaidehi S. Dedania, MD, from the New York University (NYU) Langone Health and the Grossman School of Medicine, spoke with the Eye Care Network at this year's AAO meeting held in Chicago, Illinois. She ...

In a presentation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Lu, MD, a retina specialist at Johns Hopkins Medicine, discussed the application of large language ...

David Eichenbaum, MD and Riad Sherif, MD, CEO of Oculis will present the updates with additional info on topline results from the ACUITY Phase 2 trial of OCS-05 for the treatment of acute optic ...

Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might ...

A newly published Chinese study found increased numbers of cases with acute macular neuroretinopathy (AMN) and other deficits associated with the COVID-19 outbreak, 1 reported Xiaojia Song, MD, from ...

The Eye Care Network team was on site to share key data and interview presenters at the annual meeting held in Chicago, Illinois. The annual American Academy of Ophthalmology meeting was held in ...

Dr. Mammo discussed this evolution and how to choose patients who would best benefit from GA therapy. Clinicians’ attitudes toward geography atrophy (GA) and treatment have been changing in the short ...

A $6.4 million grant over 5 years from the National Institutes of Health’s National Eye Institute was awarded conduct drug development work and investigational new drug (IND)-enabling toxicology ...

A team of researchers at the Ohio State University found that in mice an enzyme related to cell growth and division is a culprit in the blood vessel invasion in the back of the eye that causes blurred ...

Ferhina S. Ali, MD, discussed the real-world efficacy and durability of next-generation anti-VEGF agents like faricimab and aflibercept 8 mg, emphasizing how large-scale data offers insights into ...

The company noted that its GalOmic pipeline includes ETX-407 for the treatment of dry age-related macular degeneration (AMD). e-therapeutics plc, shared business updates across a variety of areas.